Premium
Biomedical Innovation: Lessons From the Past and Perspectives for the Future
Author(s) -
Munos BH
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.456
Subject(s) - enthusiasm , pharmaceutical industry , revenue , biopharmaceutics , business process reengineering , automation , chief executive officer , data science , computer science , engineering , business , marketing , management , microbiology and biotechnology , chemistry , economics , psychology , biology , finance , pharmacognosy , social psychology , mechanical engineering , biochemistry , lean manufacturing , biological activity , in vitro
Back around the turn of the millennium, the future of the pharmaceutical industry was bright. Amazing technologies were converging to enable a top‐to‐bottom reengineering of drug research and development (R&D). The “omics,” combinatorial chemistry, high‐throughput screening, robotic automation, and systems biology, promised to bring order and method to drug research's bewildering complexity. Pharmaceutical executives—many of whom were ill at ease with their scientists' freewheeling ways—were excited. Gushing with an enthusiasm that was typical of the times, a former industry Chief Executive Officer spoke glowingly of the launch of “two to three new blockbusters… each year” driving a quadrupling of revenues.[1][, 2014]